ArticleCommunications medicine2026
Age-related loss of Y chromosome is associated with mortality after ST-segment elevation myocardial infarction.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile loss of Y chromosome (LOY), a common somatic alteration with aging, has been associated with cardiovascular diseases, its specific impact on ST-segment elevation myocardial infarction (STEMI) remains underexplored.
methodsThis study enrolled 928 males undergoing primary percutaneous coronary intervention for STEMI to investigate the impact of LOY in blood cells on all-cause mortality. LOY was measured in males using droplet digital polymerase chain reaction technique. The primary outcome was all-cause mortality.
resultsDuring a median of 3.99-year follow-up, 93 males (10.0%) died. Of these, 39 (4.2%) died within 1 year, 56 (6.0%) within 2 years, and 67 (7.2%) within 3 years. Compared to males with LOY < 18% (the 90th percentile), those with LOY ≥ 18% had an increased mortality after multivariable adjustment including age, with adjusted hazard ratios (HRs) of 2.45 (95% confidence interval [CI]: 1.16-5.15; P = 0.018), 2.11 (95% CI: 1.11-4.01; P = 0.024), and 1.88 (95% CI: 1.02-3.45; P = 0.043) at 1-, 2-, and 3-year follow-up, respectively. Among males without prior MI, those with LOY ≥ 18% have higher mortality than those with LOY < 18% (adjusted HR 1.93; 95% CI: 1.01-3.67; P = 0.045), whereas no significant association is observed in males with prior MI.
conclusionsLOY ( ≥ 18%) is associated with an increased 1-, 2-, and 3-year mortality in male STEMI patients and may serve as a potential biomarker for risk stratification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.